Sfoglia per Autore
Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes
2026-01-01 Conte, Benedetta; Brasó-Maristany, Fara; Pascual, Tomás; Hernando, Cristina; Vázquez, Silvia; Blanch, Salvador; Oliveira, Mafalda; Virizuela, Juan Antonio; Muñoz, Montserrat; Seguí, Elia; Rodriguez Hernández, Adela; Vidal Losada, Maria Jesus; Galván, Patricia; Castillo, Oleguer; Blasco, Paula; Alva, Manuel; Chic, Nuria; Sanfeliu, Esther; Cano-Crespo, Sara; Salvador, Fernando; Villacampa, Guillermo; Villanueva, Lorea; Ferrero-Cafiero, Juan Manuel; Vivancos, Ana; Prat, Aleix; Ciruelos, Eva
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis
2025-01-01 Taglialatela, Ida; Ruffilli, Beatrice; Conte, Benedetta; D'Avanzo, Francesca; Rossi, Valentina; Nardin, Simone; Gennari, Alessandra
Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study
2025-01-01 Rodriguez-Hernandez, A; Martínez-Sáez, O; Brasó-Maristany, F; Conte, B; Gómez, R; García-Fructuoso, I; Fratini, B; Segui, E; Potrony, M; Sanfeliu, E; Cobo, S; Galvan, P; Moreno, L; Grau, E; Aceituno, M R; Puig-Butille, J A; Oriola, J; Goberna, G; Blasco, P; Castillo, O; Sirenko, V; Aguirre, A; Vidal, M; Muñoz, M; Ramon Y Cajal, T; Balaguer, F; Prat, A; Adamo, B
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis
2025-01-01 Schettini, Francesco; Nucera, Sabrina; Di Grazia, Giuseppe; Giudici, Fabiola; Strina, Carla; Milani, Manuela; Tancredi, Richard; Conte, Benedetta; Criscitiello, Carmen; Giuliano, Mario; Lambertini, Matteo; Sánchez-Bayona, Rodrigo; Pascual, Tomás; Arpino, Grazia; Del Mastro, Lucia; Vigneri, Paolo; Cristofanilli, Massimo; Rugo, Hope S; Gennari, Alessandra; Curigliano, Giuseppe; Generali, Daniele
Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management
2025-01-01 Nardin, Simone; Ruffilli, Beatrice; Costantini, Pietro; Mollace, Rocco; Taglialatela, Ida; Pagnesi, Matteo; Chiarito, Mauro; Soldato, Davide; Cao, Davide; Conte, Benedetta; Verdoia, Monica; Gennari, Alessandra; Nardin, Matteo
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
2025-01-01 Angelats, L.; Paré, L.; Rubio-Perez, C.; Sanfeliu, E.; González, A.; Seguí, E.; Villacampa, G.; Marín-Aguilera, M.; Pernas, S.; Conte, B.; Albarrán-Fernández, V.; Martínez-Sáez, O.; Aguirre, Á.; Galván, P.; Fernandez-Martinez, A.; Cobo, S.; Rey, M.; Martínez-Romero, A.; Walbaum, B.; Schettini, F.; Vidal, M.; Buckingham, W.; Muñoz, M.; Adamo, B.; Agrawal, Y.; Guedan, S.; Pascual, T.; Agudo, J.; Grzelak, M.; Borcherding, N.; Heyn, H.; Vivancos, A.; Parker, J. S.; Villagrasa, P.; Perou, C. M.; Prat, A.; Brasó-Maristany, F.
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial
2025-01-01 Seguí, E; Brasó-Maristany, F; Pascual, T; Sanfeliu, E; Victoria, I; Saura, C; Hierro, C; López-González, A; Izarzugaza, Y; Ciruelos, E; Gavilá, J; Racca, F; Cejalvo, J M; Amillano, K; Paz-Ares, L; Juan, M; Felip, E; Garralda, E; González, B; Arance, A; Martín-Liberal, J; Conte, B; Walbaum, B; Indacochea, A; Castillo, O; Blasco, P; Pardo, F; Aguirre, Á; Sirenko, V; González, X; Galván, P; Vivancos, A; Ferrero-Cafiero, J M; Mulero-Sánchez, A; Salvador, F; Villacampa, G; Mesía, R; Cervantes, A; Prat, A; Tabernero, J
Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management
2025-01-01 Nardin, Simone; Ruffilli, Beatrice; Landolfo, Tommaso Lupo; Isingrini, Giulia; Taglialatela, Ida; Delbarba, Andrea; D'Avanzo, Francesca; Rossi, Valentina; Celentano, Eduardo; Conte, Benedetta; Nardin, Matteo; Gennari, Alessandra
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
2024-01-01 Martin, M.; Stecklein, S. R.; Gluz, O.; Villacampa, G.; Monte-Millan, M.; Nitz, U.; Cobo, S.; Christgen, M.; Braso-Maristany, F.; Alvarez, E. L.; Echavarria, I.; Conte, B.; Kuemmel, S.; Bueno-Muino, C.; Jerez, Y.; Kates, R.; Cebollero, M.; Kolberg-Liedtke, C.; Bueno, O.; Garcia-Saenz, J. A.; Moreno, F.; Grischke, E. -M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Wuerstleins, R.; Graeser, M.; Zu Eulenburg, C.; Kreipe, H. H.; Gomez, H.; Massarrah, T.; Herrero, B.; Pare, L.; Bohn, U.; Lopez-Tarruella, S.; Vivancos, A.; Sanfeliu, E.; Parker, J. S.; Perou, C. M.; Villagrasa, P.; Prat, A.; Sharma, P.; Harbeck, N.
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial
2024-01-01 Poggio, F.; Blondeaux, E.; Tagliamento, M.; Perachino, M.; Nardin, S.; Conte, B.; Giuliano, M.; Arpino, G.; De Laurentiis, M.; Gravina, A.; Bisagni, G.; Rimanti, A.; Turletti, A.; Nisticò, C.; Magnolfi, E.; Gasparro, S.; Fabi, A.; Garrone, O.; Alicicco, M. G.; Urracci, Y.; Poletti, P.; Correale, P.; Molinelli, C.; Fozza, A.; Puglisi, F.; Colantuoni, G.; Fregatti, P.; Boni, L.; Lambertini, M.; Del Mastro, L.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies
2024-01-01 Conte, B; Brasó-Maristany, F; Hernández, Ar; Pascual, T; Villacampa, G; Schettini, F; Losada, Mjv; Seguí, E; Angelats, L; Garcia-Fructuoso, I; Gómez-Bravo, R; Lorman-Carbó, N; Paré, L; Marín-Aguilera, M; Martínez-Sáez, O; Adamo, B; Sanfeliu, E; Fratini, B; Falato, C; Chic, N; Vivancos, A; Villagrasa, P; Staaf, J; Parker, Js; Perou, Cm; Prat, A
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
2023-01-01 BRASÓ-MARISTANY, F; Griguolo, G; Chic, N; Pascual, T; Paré, L; Maues, J; Galván, P; Dieci, Mv; Miglietta, F; Giarratano, T; MARTÍNEZ-SÁEZ, O; MARÍN-AGUILERA, M; Schettini, F; Conte, B; Angelats, L; Vidal, M; Adamo, B; Muñoz, M; Sanfeliu, E; González, B; Vivancos, A; Villagrasa, P; Parker, Js; Perou, Cm; Conte, P; Prat, A; Guarneri, V
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
2023-01-01 Schettini, F; MARTÍNEZ-SÁEZ, O; Falato, C; DE SANTO, I; Conte, B; GARCIA-FRUCTUOSO, I; GOMEZ-BRAVO, R; Segúí, E; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Vidal, M; Adamo, B; Muñoz, M; Pascual, T; Ciruelos, E; Perou, Cm; Carey, La; Prat, A
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials
2023-01-01 Conte, Benedetta; Boni, Luca; Bisagni, Giancarlo; Durando, Antonio; Sanna, Giovanni; Gori, Stefania; Garrone, Ornella; Tamberi, Stefano; De Placido, Sabino; Schettini, Francesco; Pazzola, Antonio; Ponzone, Riccardo; Montemurro, Filippo; Lunardi, Gianluigi; Notaro, Rosario; De Angioletti, Maria; Turletti, Anna; Mansutti, Mauro; Puglisi, Fabio; Frassoldati, Antonio; Porpiglia, Mauro; Fabi, Alessandra; Generali, Daniele; Scognamiglio, Giovanni; Rossi, Maura; Brasó Maristany, Fara; Prat, Aleix; Cardinali, Barbara; Piccioli, Patrizia; Serra, Martina; Lastraioli, Sonia; Bighin, Claudia; Poggio, Francesca; Lambertini, Matteo; Del Mastro, Lucia
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives
2023-01-01 Sirico, M; Virga, A; Conte, B; Urbini, M; Ulivi, P; Gianni, C; Merloni, F; Palleschi, M; Gasperoni, M; Curcio, A; Saha, D; Buono, G; Muñoz, M; DE GIORGI, U; Schettini, F.
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial
2023-01-01 Conte, B; Montemurro, F; Levaggi, A; Blondeaux, E; Molinelli, C; Cardinali, B; Poggio, F; Buzzatti, G; Bighin, C; Lambertini, M; DEL MASTRO, L
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence
2022-01-01 Conte, B.; Soldato, D.; Razeti, M. G.; Fregatti, P.; de Azambuja, E.; Schettini, F.; Prat, A.; Del Mastro, L.; Lambertini, M.
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
2022-01-01 Prat, A; Guarneri, V; Pascual, T; BRASÓ-MARISTANY, F; Sanfeliu, E; Paré, L; Schettini, F; Martínez, D; Jares, P; Griguolo, G; Dieci, Mv; Cortés, J; LLOMBART-CUSSAC, A; Conte, B; MARÍN-AGUILERA, M; Chic, N; PUIG-BUTILLÉ, Ja; Martínez, A; Galván, P; Tsai, Yh; GONZÁLEZ-FARRÉ, B; Mira, A; Vivancos, A; Villagrasa, P; Parker, Js; Conte, P; Perou, Cm
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate
2022-01-01 Poggio, F; Tagliamento, M; Ceppi, M; Bruzzone, M; Conte, B; Fregatti, P; Punie, K; DE AZAMBUJA, E; DEL MASTRO, L; Lambertini, M
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
2022-01-01 Schettini, F; Segúí, E; Conte, B; Sanfeliu, E; GONZÁLEZ-FARRE, B; Jares, P; VIDAL-SICART, S; Ganau, S; Cebrecos, I; BRASÓ-MARISTANY, F; Muñoz, M; Prat, A; Vidal, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes | 1-gen-2026 | Conte, Benedetta; Brasó-Maristany, Fara; Pascual, Tomás; Hernando, Cristina; Vázquez, Silvia; Blanch, Salvador; Oliveira, Mafalda; Virizuela, Juan Antonio; Muñoz, Montserrat; Seguí, Elia; Rodriguez Hernández, Adela; Vidal Losada, Maria Jesus; Galván, Patricia; Castillo, Oleguer; Blasco, Paula; Alva, Manuel; Chic, Nuria; Sanfeliu, Esther; Cano-Crespo, Sara; Salvador, Fernando; Villacampa, Guillermo; Villanueva, Lorea; Ferrero-Cafiero, Juan Manuel; Vivancos, Ana; Prat, Aleix; Ciruelos, Eva | |
| Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis | 1-gen-2025 | Taglialatela, Ida; Ruffilli, Beatrice; Conte, Benedetta; D'Avanzo, Francesca; Rossi, Valentina; Nardin, Simone; Gennari, Alessandra | |
| Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study | 1-gen-2025 | Rodriguez-Hernandez, A; Martínez-Sáez, O; Brasó-Maristany, F; Conte, B; Gómez, R; García-Fructuoso, I; Fratini, B; Segui, E; Potrony, M; Sanfeliu, E; Cobo, S; Galvan, P; Moreno, L; Grau, E; Aceituno, M R; Puig-Butille, J A; Oriola, J; Goberna, G; Blasco, P; Castillo, O; Sirenko, V; Aguirre, A; Vidal, M; Muñoz, M; Ramon Y Cajal, T; Balaguer, F; Prat, A; Adamo, B | |
| Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis | 1-gen-2025 | Schettini, Francesco; Nucera, Sabrina; Di Grazia, Giuseppe; Giudici, Fabiola; Strina, Carla; Milani, Manuela; Tancredi, Richard; Conte, Benedetta; Criscitiello, Carmen; Giuliano, Mario; Lambertini, Matteo; Sánchez-Bayona, Rodrigo; Pascual, Tomás; Arpino, Grazia; Del Mastro, Lucia; Vigneri, Paolo; Cristofanilli, Massimo; Rugo, Hope S; Gennari, Alessandra; Curigliano, Giuseppe; Generali, Daniele | |
| Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management | 1-gen-2025 | Nardin, Simone; Ruffilli, Beatrice; Costantini, Pietro; Mollace, Rocco; Taglialatela, Ida; Pagnesi, Matteo; Chiarito, Mauro; Soldato, Davide; Cao, Davide; Conte, Benedetta; Verdoia, Monica; Gennari, Alessandra; Nardin, Matteo | |
| Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer | 1-gen-2025 | Angelats, L.; Paré, L.; Rubio-Perez, C.; Sanfeliu, E.; González, A.; Seguí, E.; Villacampa, G.; Marín-Aguilera, M.; Pernas, S.; Conte, B.; Albarrán-Fernández, V.; Martínez-Sáez, O.; Aguirre, Á.; Galván, P.; Fernandez-Martinez, A.; Cobo, S.; Rey, M.; Martínez-Romero, A.; Walbaum, B.; Schettini, F.; Vidal, M.; Buckingham, W.; Muñoz, M.; Adamo, B.; Agrawal, Y.; Guedan, S.; Pascual, T.; Agudo, J.; Grzelak, M.; Borcherding, N.; Heyn, H.; Vivancos, A.; Parker, J. S.; Villagrasa, P.; Perou, C. M.; Prat, A.; Brasó-Maristany, F. | |
| Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial | 1-gen-2025 | Seguí, E; Brasó-Maristany, F; Pascual, T; Sanfeliu, E; Victoria, I; Saura, C; Hierro, C; López-González, A; Izarzugaza, Y; Ciruelos, E; Gavilá, J; Racca, F; Cejalvo, J M; Amillano, K; Paz-Ares, L; Juan, M; Felip, E; Garralda, E; González, B; Arance, A; Martín-Liberal, J; Conte, B; Walbaum, B; Indacochea, A; Castillo, O; Blasco, P; Pardo, F; Aguirre, Á; Sirenko, V; González, X; Galván, P; Vivancos, A; Ferrero-Cafiero, J M; Mulero-Sánchez, A; Salvador, F; Villacampa, G; Mesía, R; Cervantes, A; Prat, A; Tabernero, J | |
| Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management | 1-gen-2025 | Nardin, Simone; Ruffilli, Beatrice; Landolfo, Tommaso Lupo; Isingrini, Giulia; Taglialatela, Ida; Delbarba, Andrea; D'Avanzo, Francesca; Rossi, Valentina; Celentano, Eduardo; Conte, Benedetta; Nardin, Matteo; Gennari, Alessandra | |
| TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy | 1-gen-2024 | Martin, M.; Stecklein, S. R.; Gluz, O.; Villacampa, G.; Monte-Millan, M.; Nitz, U.; Cobo, S.; Christgen, M.; Braso-Maristany, F.; Alvarez, E. L.; Echavarria, I.; Conte, B.; Kuemmel, S.; Bueno-Muino, C.; Jerez, Y.; Kates, R.; Cebollero, M.; Kolberg-Liedtke, C.; Bueno, O.; Garcia-Saenz, J. A.; Moreno, F.; Grischke, E. -M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Wuerstleins, R.; Graeser, M.; Zu Eulenburg, C.; Kreipe, H. H.; Gomez, H.; Massarrah, T.; Herrero, B.; Pare, L.; Bohn, U.; Lopez-Tarruella, S.; Vivancos, A.; Sanfeliu, E.; Parker, J. S.; Perou, C. M.; Villagrasa, P.; Prat, A.; Sharma, P.; Harbeck, N. | |
| Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial | 1-gen-2024 | Poggio, F.; Blondeaux, E.; Tagliamento, M.; Perachino, M.; Nardin, S.; Conte, B.; Giuliano, M.; Arpino, G.; De Laurentiis, M.; Gravina, A.; Bisagni, G.; Rimanti, A.; Turletti, A.; Nisticò, C.; Magnolfi, E.; Gasparro, S.; Fabi, A.; Garrone, O.; Alicicco, M. G.; Urracci, Y.; Poletti, P.; Correale, P.; Molinelli, C.; Fozza, A.; Puglisi, F.; Colantuoni, G.; Fregatti, P.; Boni, L.; Lambertini, M.; Del Mastro, L. | |
| A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies | 1-gen-2024 | Conte, B; Brasó-Maristany, F; Hernández, Ar; Pascual, T; Villacampa, G; Schettini, F; Losada, Mjv; Seguí, E; Angelats, L; Garcia-Fructuoso, I; Gómez-Bravo, R; Lorman-Carbó, N; Paré, L; Marín-Aguilera, M; Martínez-Sáez, O; Adamo, B; Sanfeliu, E; Fratini, B; Falato, C; Chic, N; Vivancos, A; Villagrasa, P; Staaf, J; Parker, Js; Perou, Cm; Prat, A | |
| HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 | 1-gen-2023 | BRASÓ-MARISTANY, F; Griguolo, G; Chic, N; Pascual, T; Paré, L; Maues, J; Galván, P; Dieci, Mv; Miglietta, F; Giarratano, T; MARTÍNEZ-SÁEZ, O; MARÍN-AGUILERA, M; Schettini, F; Conte, B; Angelats, L; Vidal, M; Adamo, B; Muñoz, M; Sanfeliu, E; González, B; Vivancos, A; Villagrasa, P; Parker, Js; Perou, Cm; Conte, P; Prat, A; Guarneri, V | |
| Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis | 1-gen-2023 | Schettini, F; MARTÍNEZ-SÁEZ, O; Falato, C; DE SANTO, I; Conte, B; GARCIA-FRUCTUOSO, I; GOMEZ-BRAVO, R; Segúí, E; Chic, N; BRASÓ-MARISTANY, F; Paré, L; Vidal, M; Adamo, B; Muñoz, M; Pascual, T; Ciruelos, E; Perou, Cm; Carey, La; Prat, A | |
| SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials | 1-gen-2023 | Conte, Benedetta; Boni, Luca; Bisagni, Giancarlo; Durando, Antonio; Sanna, Giovanni; Gori, Stefania; Garrone, Ornella; Tamberi, Stefano; De Placido, Sabino; Schettini, Francesco; Pazzola, Antonio; Ponzone, Riccardo; Montemurro, Filippo; Lunardi, Gianluigi; Notaro, Rosario; De Angioletti, Maria; Turletti, Anna; Mansutti, Mauro; Puglisi, Fabio; Frassoldati, Antonio; Porpiglia, Mauro; Fabi, Alessandra; Generali, Daniele; Scognamiglio, Giovanni; Rossi, Maura; Brasó Maristany, Fara; Prat, Aleix; Cardinali, Barbara; Piccioli, Patrizia; Serra, Martina; Lastraioli, Sonia; Bighin, Claudia; Poggio, Francesca; Lambertini, Matteo; Del Mastro, Lucia | |
| Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives | 1-gen-2023 | Sirico, M; Virga, A; Conte, B; Urbini, M; Ulivi, P; Gianni, C; Merloni, F; Palleschi, M; Gasperoni, M; Curcio, A; Saha, D; Buono, G; Muñoz, M; DE GIORGI, U; Schettini, F. | |
| Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial | 1-gen-2023 | Conte, B; Montemurro, F; Levaggi, A; Blondeaux, E; Molinelli, C; Cardinali, B; Poggio, F; Buzzatti, G; Bighin, C; Lambertini, M; DEL MASTRO, L | |
| De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence | 1-gen-2022 | Conte, B.; Soldato, D.; Razeti, M. G.; Fregatti, P.; de Azambuja, E.; Schettini, F.; Prat, A.; Del Mastro, L.; Lambertini, M. | |
| Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer | 1-gen-2022 | Prat, A; Guarneri, V; Pascual, T; BRASÓ-MARISTANY, F; Sanfeliu, E; Paré, L; Schettini, F; Martínez, D; Jares, P; Griguolo, G; Dieci, Mv; Cortés, J; LLOMBART-CUSSAC, A; Conte, B; MARÍN-AGUILERA, M; Chic, N; PUIG-BUTILLÉ, Ja; Martínez, A; Galván, P; Tsai, Yh; GONZÁLEZ-FARRÉ, B; Mira, A; Vivancos, A; Villagrasa, P; Parker, Js; Conte, P; Perou, Cm | |
| Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate | 1-gen-2022 | Poggio, F; Tagliamento, M; Ceppi, M; Bruzzone, M; Conte, B; Fregatti, P; Punie, K; DE AZAMBUJA, E; DEL MASTRO, L; Lambertini, M | |
| Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. | 1-gen-2022 | Schettini, F; Segúí, E; Conte, B; Sanfeliu, E; GONZÁLEZ-FARRE, B; Jares, P; VIDAL-SICART, S; Ganau, S; Cebrecos, I; BRASÓ-MARISTANY, F; Muñoz, M; Prat, A; Vidal, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile